Clinical-stage immuno-oncology biotech Imugene Ltd (ASX:IMU, OTC:IUGNF) has been making significant strides in the development of therapies targeting a range of cancers.
In this episode of After Market, MD and CEO Leslie Chong tells Susanna Nelson about the company's Phase 1 metastatic advanced solid tumours, or MAST, trial, which has been designed to evaluate the safety and efficacy of the cancer-killing virus CF33-hNIS (VAXINIA). Read the news story here.
You can follow After Market on Spotify Music and Apple Podcasts to keep up with the latest episodes.